Quintiles to boost early-phase testing lab with Advion Biosciences acquisition
Quintiles says it will buy US bioanalytical lab Advion BioServices citing a pharmaceutical industry shift towards more thorough laboratory testing as motivation.
Advion, which is the US contract research organisation’s (CRO) third acquisition in as many weeks, provides pharmacokinetic and pharmacodynamics analysis services for a range of drug developers, including Pharma major Eli Lilly which farmed out all of its testing work to the firm in March.
Quintiles said increasing late-phase attrition rates are driving demand for more preclinical and early clinical stage bioanalytical anaylsis as developers seek to make their R&D spending as efficient as possible.
Advion operates three labs in the US in Ithaca in New York, Manassas in Virginia and one at the Purdue Research Park in Indianapolis, Indiana which was set up as a centre of excellence following the firm’s deal with Lilly.
